Akcea to Cut Staff 10% in Wake of FDA Rejection of Rare Disease Drug

Akcea Therapeutics is laying off 10 percent of its workforce, a move that follows the FDA’s rejection of the company’s rare disease drug last week.

Cambridge, MA-based Akcea (NASDAQ: AKCA) said in a regulatory filing Thursday that the board of directors approved the reorganization plan on Sept. 2. Affected employees were notified Thursday. As of February, Akcea employed 100, according to its annual report. But the company had been beefing up its staff in recent months in preparation for a commercial launch of the drug, volanesorsen (Waylivra). The FDA’s rejection last week scuttled those plans. Akcea said in the filing… Read more »

Reprints | Share:          

UNDERWRITERS AND PARTNERS